Invasive pneumococcal disease in the immunocompromised host.

A normal constituent of the human upper respiratory flora, Streptococcus pneumoniae also produces respiratory tract infections that progress to invasive disease at high rates in specific risk groups. The individual factors that contribute to the development of invasive pneumococcal disease in this distinct minority of persons, include immune (both specific and innate), genetic, and environmental elements. Specific defects in host responses may involve age, deficiencies in levels of antibodies and complement factors, and splenic dysfunction. Combinations of these immune defects contribute to the increased rates of invasive pneumococcal disease in patients with sickle cell disease, nephrotic syndrome, neoplasms, and underlying medical conditions such as diabetes and alcoholic liver disease. The number of risk factors are greatest and the rates of invasive disease are highest in patients with HIV-1 infection, which has emerged as a major risk factor for serious S. pneumoniae infection worldwide.

[1]  J. Ojoo,et al.  Responsiveness of human immunodeficiency virus type 1-infected Kenyan women with or without prior pneumococcal disease to pneumococcal vaccine. , 1997, The Journal of infectious diseases.

[2]  D. Musher,et al.  Emergence of antibody to capsular polysaccharides of Streptococcus pneumoniae during outbreaks of pneumonia: association with nasopharyngeal colonization. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  D. Musher,et al.  Colonization by Streptococcus pneumoniae among human immunodeficiency virus-infected adults: prevalence of antibiotic resistance, impact of immunization, and characterization by polymerase chain reaction with BOX primers of isolates from persistent S. pneumoniae carriers. , 1997, The Journal of infectious diseases.

[4]  D. Rimland,et al.  Community‐acquired bacteremia in HIV‐positive patients: protective benefit of co‐trimoxazole , 1996, AIDS.

[5]  S. Swindells,et al.  Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine. , 1996, The Journal of infectious diseases.

[6]  F. Altice,et al.  Invasive pneumococcal disease: clinical features, serotypes, and antimicrobial resistance patterns in cases involving patients with and without human immunodeficiency virus infection. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Craven,et al.  Causes of fever in patients infected with human immunodeficiency virus who were admitted to Boston City Hospital. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  T. Peláez,et al.  Recurrent pneumococcal bacteremia. A warning of immunodeficiency. , 1996, Archives of internal medicine.

[9]  G. Castellani,et al.  Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  W. Timens,et al.  Human immune response to pneumococcal polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal zone B cells and follicular dendritic cells. , 1996, The Journal of allergy and clinical immunology.

[11]  F. Plummer,et al.  Invasive pneumococcal disease in a cohort of predominantly HIV-1 infected female sex-workers in Nairobi, Kenya , 1996, The Lancet.

[12]  M. Guiguet,et al.  Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  D. Musher,et al.  Association of invasive pneumococcal disease with season, atmospheric conditions, air pollution, and the isolation of respiratory viruses. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  M. Steinhoff,et al.  Effect of human immunodeficiency virus type 1 infection on the antibody response to a glycoprotein conjugate pneumococcal vaccine: results from a randomized trial. , 1996, The Journal of infectious diseases.

[15]  J. Eskola,et al.  New vaccines for prevention of pneumococcal infections. , 1996, Annals of medicine.

[16]  P. Hopewell,et al.  Impaired natural immunity to pneumolysin during human immunodeficiency virus infection in the United States and Africa. , 1995, American journal of respiratory and critical care medicine.

[17]  M. Goldman,et al.  Differential effect of human immunodeficiency virus infection on the IgA and IgG antibody responses to pneumococcal vaccine. , 1995, The Journal of infectious diseases.

[18]  J. Paul,et al.  Streptococcus pneumoniae resistant to penicillin and tetracycline associated with HIV seropositivity , 1995, The Lancet.

[19]  Richard D Moore,et al.  Community-acquired pneumonia: impact of immune status. , 1995 .

[20]  S. Miller,et al.  Anti-pneumococcal antibody levels three to seven years after first booster immunization in children with sickle cell disease, and after a second booster. , 1995, The Journal of pediatrics.

[21]  R. Hirschtick,et al.  Bacterial pneumonia in persons infected with the human immunodeficiency virus. Pulmonary Complications of HIV Infection Study Group. , 1995, The New England journal of medicine.

[22]  E. Janoff,et al.  Antibody class and subclass responses to pneumococcal polysaccharides following immunization of human immunodeficiency virus-infected patients. , 1995, The Journal of infectious diseases.

[23]  P. Hopewell,et al.  Impact of Streptococcus pneumoniae bacteremia and human immunodeficiency virus type 1 on oral mucosal immunity. , 1995, The Journal of infectious diseases.

[24]  P. Van Royen,et al.  Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease. , 1995, The Journal of infectious diseases.

[25]  K. Holmes,et al.  Reducing the impact of opportunistic infections in patients with HIV infection. New guidelines. , 1995, JAMA.

[26]  J. Ruiz-Contreras,et al.  Sepsis in children with human immunodeficiency virus infection. The Madrid HIV Pediatric Infection Collaborative Study Group. , 1995, The Pediatric infectious disease journal.

[27]  M. Wallace,et al.  Response of recent human immunodeficiency virus seroconverters to the pneumococcal polysaccharide vaccine and Haemophilus influenzae type b conjugate vaccine. , 1995, The Journal of infectious diseases.

[28]  C. Giaquinto,et al.  Antibody responses to Haemophilus influenzae type b and Streptococcus pneumoniae vaccines in children with human immunodeficiency virus infection. , 1995, The Pediatric infectious disease journal.

[29]  P. Moore,et al.  Risk factors for adverse outcome in persons with pneumococcal pneumonia. , 1995, Chest.

[30]  P. Andrew,et al.  Dual function of pneumolysin in the early pathogenesis of murine pneumococcal pneumonia. , 1995, The Journal of clinical investigation.

[31]  R. Gelber,et al.  A controlled trial of intravenous immune globulin for the prevention of serious bacterial infections in children receiving zidovudine for advanced human immunodeficiency virus infection. Pediatric AIDS Clinical Trials Group. , 1994, The New England journal of medicine.

[32]  R. Lütticken,et al.  Serum antibody responses to vaccination with 23-valent pneumococcal vaccine in splenectomized patients. , 1994, Zentralblatt fur Bakteriologie : international journal of medical microbiology.

[33]  D. Musher,et al.  An epidemic of pneumococcal disease in an overcrowded, inadequately ventilated jail. , 1994, The New England journal of medicine.

[34]  D. Niewoehner,et al.  Pneumolysin activates phospholipase A in pulmonary artery endothelial cells , 1994, Infection and immunity.

[35]  P. Selwyn,et al.  Medical care for injection-drug users with human immunodeficiency virus infection. , 1994, The New England journal of medicine.

[36]  H. Gayle,et al.  The public health implications of AIDS research in Africa. , 1994, JAMA.

[37]  W. Borkowsky,et al.  Streptococcus pneumoniae in human immunodeficiency virus type 1‐infected children , 1994, The Pediatric infectious disease journal.

[38]  D. Parks,et al.  The epidemiology of invasive pneumococcal disease in Alaska, 1986-1990--ethnic differences and opportunities for prevention. , 1994, The Journal of infectious diseases.

[39]  T. Marrie Pneumonia and carcinoma of the lung. , 1994, The Journal of infection.

[40]  E. Janoff,et al.  Antibodies to pneumococcal capsular polysaccharides in children with human immunodeficiency virus infection given polyvalent pneumococcal vaccine. , 1994, The Journal of pediatrics.

[41]  R. Tressler,et al.  Invasive pneumococcal disease among infected and uninfected children of mothers with human immunodeficiency virus infection. , 1994, The Journal of pediatrics.

[42]  W. Andiman,et al.  Invasive bacterial infections in children born to women infected with human immunodeficiency virus type 1. , 1994, The Journal of pediatrics.

[43]  L. Mofenson,et al.  Crossover of placebo patients to intravenous immunoglobulin confirms efficacy for prophylaxis of bacterial infections and reduction of hospitalizations in human immunodeficiency virus‐infected children , 1994, The Pediatric infectious disease journal.

[44]  J. D. de Jong,et al.  Antibody response to influenza, tetanus and pneumococcal vaccines in HIV‐seropositive individuals in relation to the number of CD4+ lymphocytes , 1994, AIDS.

[45]  I. Ocaña,et al.  Bacterial pneumonia in HIV-infected patients: a prospective study of 68 episodes. , 1994, The European respiratory journal.

[46]  F. Rodeghiero,et al.  Fulminant sepsis in adults splenectomized for Hodgkin's disease. , 1993, Haematologica.

[47]  J. Rubins,et al.  Identification of hydrogen peroxide as a Streptococcus pneumoniae toxin for rat alveolar epithelial cells , 1993, Infection and Immunity.

[48]  M. Falguera,et al.  Prevalence and outcome of pneumococcal carrier human immunodeficiency virus-infected patients. , 1993, The Journal of infectious diseases.

[49]  D. Musher,et al.  Antibody to capsular polysaccharides of Streptococcus pneumoniae: prevalence, persistence, and response to revaccination. , 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  D. Jarjoura,et al.  Pneumococcal bacteremia in three community teaching hospitals from 1980 to 1989. , 1993, Chest.

[51]  I. Julander,et al.  Deaths in bacteremic pneumococcal pneumonia. A comparison of two populations--Huntington, WVa, and Stockholm, Sweden. , 1993, Chest.

[52]  H. Sacks,et al.  Influenza and pneumococcal vaccination of HIV-infected patients: a policy analysis. , 1993, The American journal of medicine.

[53]  J. Lortan,et al.  Relationship of in vitro phagocytosis of serotype 14 Streptococcus pneumoniae to specific class and IgG subclass antibody levels in healthy adults , 1993, Clinical and experimental immunology.

[54]  P. Thompson,et al.  Streptococcus pneumoniae colonization, bacteremia, and immune response among persons with human immunodeficiency virus infection. , 1993, The Journal of infectious diseases.

[55]  H. Waskin,et al.  A controlled trial of trimethoprim-sulfamethoxazole or aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. , 1992, The New England journal of medicine.

[56]  M. Drucker,et al.  Epidemiology of Invasive Childhood Pneumococcal Infections in Israel , 1992 .

[57]  M. Leinonen,et al.  Epidemiology of invasive pneumococcal infections in children in Finland. , 1992, JAMA.

[58]  R. Dagan,et al.  Epidemiology of invasive childhood pneumococcal infections in Israel. The Israeli Pediatric Bacteremia and Meningitis Group. , 1992, JAMA.

[59]  P. Selwyn,et al.  Clinical manifestations and predictors of disease progression in drug users with human immunodeficiency virus infection. , 1992, The New England journal of medicine.

[60]  W. Gransden,et al.  Recurrent pneumococcal bacteremia. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[61]  D. Kilpatrick Soluble interleukin-2 receptors in recurrent miscarriage and the effect of leukocyte immunotherapy. , 1992, Immunology letters.

[62]  D. Wara,et al.  Low number of antibody producing cells in patients with sickle cell anemia. , 1992, Immunology letters.

[63]  Fenguangzhai Song CD , 1992 .

[64]  N. Bennett,et al.  Pneumococcal bacteremia in Monroe County, New York. , 1992, American journal of public health.

[65]  M. Santosham,et al.  High incidence rates of invasive pneumococcal disease in the White Mountain Apache population. , 1992, Archives of internal medicine.

[66]  E. Bouza,et al.  Pneumococcal pneumonia in adult hospitalized patients infected with the human immunodeficiency virus. , 1992, Archives of internal medicine.

[67]  P. Hopewell,et al.  Pneumococcal Disease during HIV Infection , 1992, Annals of Internal Medicine.

[68]  L. Mofenson,et al.  Prophylactic Intravenous Immunoglobulin in HIV-Infected Children With CD4+ Counts of 0.20×109/L or More: Effect on Viral, Opportunistic, and Bacterial Infections , 1992 .

[69]  J. Moye,et al.  Prophylactic intravenous immunoglobulin in HIV-infected children with CD4+ counts of 0.20 x 10(9)/L or more. Effect on viral, opportunistic, and bacterial infections. The National Institute of Child Health and Human Development Intravenous Immunoglobulin Clinical Trial Study Group. , 1992, JAMA.

[70]  J. Rubins,et al.  Toxicity of pneumolysin to pulmonary endothelial cells in vitro , 1992, Infection and immunity.

[71]  F. Claas,et al.  The amplifier role of T cells in the human in vitro B cell response to type 4 pneumococcal polysaccharide. , 1992, Immunology letters.

[72]  H. Helenius,et al.  Infections and serum IgG levels in patients with chronic lymphocytic leukemia , 1992, European journal of haematology.

[73]  D. K. Kelsey,et al.  Comparison of the opsonic and complement triggering activity of human monoclonal IgG1 and IgM antibody against group B streptococci. , 1992, Journal of immunology.

[74]  M. Daha,et al.  An association between homozygous C3 deficiency and low levels of anti‐pneumococcal capsular polysaccharide antibodies , 1992, Clinical and experimental immunology.

[75]  G. Overturf,et al.  Polysaccharide encapsulated bacterial infection in sickle cell anemia: A thirty year epidemiologic experience , 1992, American journal of hematology.

[76]  V. Valtonen,et al.  Pneumococcal bacteraemia during a recent decade. , 1992, The Journal of infection.

[77]  D. Musher,et al.  Unusual manifestations of pneumococcal infection in human immunodeficiency virus-infected individuals: the past revisited. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  R. van Furth,et al.  Mechanisms of host defense against infection with Streptococcus pneumoniae. , 1992, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  G. Pesola,et al.  Pneumococcal bacteremia with pneumonia. Mortality in acquired immunodeficiency syndrome. , 1992, Chest.

[80]  D. Vlahov,et al.  Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[81]  R. Adair,et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. , 1991, The New England journal of medicine.

[82]  G. Boulnois,et al.  Structure and function of pneumolysin, the multifunctional, thiol‐activated toxin of Streptococcus pneumoniae , 1991, Molecular microbiology.

[83]  P. D. Smith,et al.  Humoral recall responses in HIV infection. Levels, specificity, and affinity of antigen-specific IgG. , 1991, Journal of immunology.

[84]  R. Auckenthaler,et al.  Mode of presentation and diagnosis of bacterial pneumonia in human immunodeficiency virus-infected patients. , 1991, The American review of respiratory disease.

[85]  G. Schiffman,et al.  Zidovudine improves response to pneumococcal vaccine among persons with AIDS and AIDS-related complex. , 1991, The Journal of infectious diseases.

[86]  L. Mofenson,et al.  Intravenous immune globulin for the prevention of bacterial infections in children with symptomatic human immunodeficiency virus infection. , 1991, The New England journal of medicine.

[87]  P. Densen,et al.  Infectious diseases associated with complement deficiencies , 1991, Clinical Microbiology Reviews.

[88]  W. Levine,et al.  Epidemiology of nontyphoidal Salmonella bacteremia during the human immunodeficiency virus epidemic. , 1991, The Journal of infectious diseases.

[89]  A. Schuchat,et al.  Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population. , 1991, JAMA.

[90]  M. Opravil,et al.  Poor antibody response after tetanus and pneumococcal vaccination in immunocompromised, HIV‐infected patients , 1991, Clinical and experimental immunology.

[91]  J. Henrichsen,et al.  Pneumococcal Infections in Splenectomized Children Are Preventable , 1991, Acta paediatrica Scandinavica.

[92]  C. Leport,et al.  Efficacy of zidovudine in preventing relapses of Salmonella bacteremia in AIDS. , 1991, The Journal of infectious diseases.

[93]  F. Puppo,et al.  Major histocompatibility gene products and human immunodeficiency virus infection. , 1991, The Journal of laboratory and clinical medicine.

[94]  I. Abramson,et al.  The evolution of lymphadenopathy and hypergammaglobulinemia are evidence for early and sustained polyclonal B lymphocyte activation during human immunodeficiency virus infection. , 1991, The Journal of infectious diseases.

[95]  G. Rutherford,et al.  The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. , 1990, The Journal of infectious diseases.

[96]  D. Warrell,et al.  Life-threatening bacteraemia in HIV-1 seropositive adults admitted to hospital in Nairobi, Kenya , 1990, The Lancet.

[97]  R. Breiman,et al.  Pneumococcal bacteremia in Charleston County, South Carolina. A decade later. , 1990, Archives of internal medicine.

[98]  E. Winsor,et al.  Neutrophil dysfunctions in sickle cell disease. , 1990, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[99]  Y. Sultan,et al.  Dexamethasone treatment for bacterial meningitis in children and adults , 1989, The Pediatric infectious disease journal.

[100]  P. Casali,et al.  CD5+ B lymphocytes, polyreactive antibodies and the human B-cell repertoire. , 1989, Immunology today.

[101]  L. Hammarström,et al.  Type‐specific anti‐pneumococcal antibody subclass response to vaccination after splenectomy with special reference to lymphoma patients , 1989, European journal of haematology.

[102]  P. Selwyn,et al.  Response to pneumococcal vaccine among asymptomatic heterosexual partners of persons with AIDS and intravenous drug users infected with human immunodeficiency virus. , 1989, The Journal of infectious diseases.

[103]  S. Frøland,et al.  Altered IgG-subclass distribution in lymph node cells and serum of adults infected with human immunodeficiency virus (HIV). , 1989, Clinical and experimental immunology.

[104]  J. Bogaerts,et al.  Bacteraemia as Predictor of HIV Infection in African Children , 1989, Acta paediatrica Scandinavica.

[105]  E. Tuomanen,et al.  Reduction of inflammation, tissue damage, and mortality in bacterial meningitis in rabbits treated with monoclonal antibodies against adhesion-promoting receptors of leukocytes , 1989, The Journal of experimental medicine.

[106]  L. Specht,et al.  Antibody response to pneumococcal vaccine in patients with early stage Hodgkin's disease , 1989, European journal of haematology.

[107]  H. Krumholz,et al.  Community-acquired bacteremia in patients with acquired immunodeficiency syndrome: clinical presentation, bacteriology, and outcome. , 1989, The American journal of medicine.

[108]  S. Gillespie Aspects of pneumococcal infection including bacterial virulence, host response and vaccination. , 1989, Journal of medical microbiology.

[109]  F. Miedema,et al.  Longitudinal study of leukocyte functions in homosexual men seroconverted for HIV: rapid and persistent loss of B cell function after HIV infection , 1989, European journal of immunology.

[110]  C. Schraer,et al.  Invasive pneumococcal disease in an Alaska native population, 1980 through 1986. , 1989, JAMA.

[111]  F. Lamothe,et al.  Surveillance of invasive Streptococcus pneumoniae infection in Quebec, Canada, from 1984 to 1986: serotype distribution, antimicrobial susceptibility, and clinical characteristics , 1989, Journal of clinical microbiology.

[112]  J. Falloon,et al.  Human immunodeficiency virus infection in children. , 1989, The Journal of pediatrics.

[113]  M. Cairo,et al.  Impaired neutrophil function in patients with AIDS or AIDS-related complex: a comprehensive evaluation. , 1988, The Journal of infectious diseases.

[114]  M. Blaser,et al.  Class-specific antibody response to pneumococcal capsular polysaccharides in men infected with human immunodeficiency virus type 1. , 1988, The Journal of infectious diseases.

[115]  A. Randomized Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. , 1988 .

[116]  A. Fauci,et al.  Impairment of neutrophil bactericidal capacity in patients with AIDS. , 1988, The Journal of infectious diseases.

[117]  P. Selwyn,et al.  Increased risk of bacterial pneumonia in HIV-infected intravenous drug users without AIDS. , 1988, AIDS.

[118]  W. Borkowsky,et al.  Bacterial infections in human immunodeficiency virus‐infected children , 1988, The Pediatric infectious disease journal.

[119]  M. Blaser,et al.  Acute antibody responses to Giardia lamblia are depressed in patients with AIDS. , 1988, The Journal of infectious diseases.

[120]  J. Hermans,et al.  Pneumococcal bacteremia in adults over a 10-year period at University Hospital, Leiden. , 1988, Reviews of infectious diseases.

[121]  R. Holman,et al.  Hypergammaglobulinemia associated with human immunodeficiency virus infection. , 1988, Monographs in allergy.

[122]  E. Garin,et al.  Pneumococcal polysaccharide immunization in patients with active nephrotic syndrome. , 1988, Nephron.

[123]  G. Schiffman,et al.  Immunoglobulin G class and subclass antibodies to pneumococcal capsular polysaccharides. , 1987, Clinical immunology and immunopathology.

[124]  E. Shapiro,et al.  Prevention of pneumococcal bacteremia in a child with acquired immunodeficiency syndrome‐related complex , 1987, The Pediatric infectious disease journal.

[125]  P. Toghill,et al.  Bacteraemia in adults after splenectomy or splenic irradiation. , 1987, The Quarterly journal of medicine.

[126]  W. R. Mccabe,et al.  Bacterial infections in adult patients with the acquired immune deficiency syndrome (AIDS) and AIDS-related complex. , 1987, The American journal of medicine.

[127]  L. Kingsley,et al.  Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. , 1987, JAMA.

[128]  T. Quinn,et al.  Demonstration of defective C3-receptor-mediated clearance by the reticuloendothelial system in patients with acquired immunodeficiency syndrome. , 1987, The Journal of clinical investigation.

[129]  T. Shah,et al.  Polymorphonuclear leukocyte-mediated, antibody-dependent cellular cytotoxicity in patients with AIDS. , 1987, The Journal of infectious diseases.

[130]  J. Lobel,et al.  Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency. , 1987, The Journal of clinical investigation.

[131]  J. Kersey,et al.  Titers of antibody to pneumococci in allogeneic bone marrow transplant recipients before and after vaccination with pneumococcal vaccine. , 1986, The Journal of infectious diseases.

[132]  R. Schreiber,et al.  Altered erythrocyte C3b receptor expression, immune complexes, and complement activation in homosexual men in varying risk groups for acquired immune deficiency syndrome. , 1986, The Journal of clinical investigation.

[133]  J. Verter,et al.  Bacteremia in sickle hemoglobinopathies. , 1986, The Journal of pediatrics.

[134]  I. Maclennan,et al.  Impaired IgG2 anti-pneumococcal antibody responses in patients with recurrent infection and normal IgG2 levels but no IgA. , 1986, Clinical and experimental immunology.

[135]  E Vichinsky,et al.  Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. , 1986, The New England journal of medicine.

[136]  J. Spika,et al.  Decline of vaccine-induced antipneumococcal antibody in children with nephrotic syndrome. , 1986, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[137]  M. Hostetter,et al.  Serotypic variations among virulent pneumococci in deposition and degradation of covalently bound C3b: implications for phagocytosis and antibody production. , 1986, The Journal of infectious diseases.

[138]  L. Hammarström,et al.  Pneumococcal antibodies of different immunoglobulin subclasses in normal and IgG subclass deficient individuals of various ages. , 1986, Acta oto-laryngologica.

[139]  B. Polsky,et al.  Bacterial pneumonia in patients with the acquired immunodeficiency syndrome. , 1986, Annals of internal medicine.

[140]  S. Sarnaik,et al.  Revaccination with polyvalent pneumococcal vaccine in children with sickle cell anemia. , 1986, The American journal of pediatric hematology/oncology.

[141]  D. Rimland,et al.  Alcoholism, leukopenia, and pneumococcal sepsis. , 2015, The American review of respiratory disease.

[142]  J. Lobel,et al.  Relation between serum opsonic activity for Streptococcus pneumoniae and complement function in sickle cell disease. , 1985, The Journal of infectious diseases.

[143]  P. Drew,et al.  Lack of effect of splenic regrowth on the reduced antibody responses to pneumococcal polysaccharides in splenectomized patients. , 1985, Clinical and experimental immunology.

[144]  D. Gray,et al.  Class and subclass anti-pneumococcal antibody responses in splenectomized patients. , 1985, Clinical and experimental immunology.

[145]  A. Rubinstein,et al.  Bacterial infection in the acquired immunodeficiency syndrome of children , 1985, Pediatric infectious disease.

[146]  T. Quinn,et al.  Defective reticuloendothelial system Fc-receptor function in patients with acquired immunodeficiency syndrome. , 1985, The Journal of infectious diseases.

[147]  P. Schur,et al.  Correlation between G2m(n) immunoglobulin allotype and human antibody response and susceptibility to polysaccharide encapsulated bacteria. , 1985, The Journal of clinical investigation.

[148]  R. Norrby,et al.  Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. , 1985, Reviews of infectious diseases.

[149]  I. Phillips,et al.  Pneumococcal bacteraemia: 325 episodes diagnosed at St Thomas's Hospital. , 1985, British medical journal.

[150]  F. D. Di Padova,et al.  Impaired antipneumococcal antibody production in patients without spleens. , 1985, British medical journal.

[151]  G. Schiffman,et al.  Pneumococcal vaccination in children with acute lymphocytic leukemia. , 1985, Medical and Pediatric Oncology.

[152]  P. Densen,et al.  Complement Deficiency States and Infection: Epidemiology, Pathogenesis and Consequences of Neisserial and Other Infections in an Immune Deficiency , 1984, Medicine.

[153]  B. Cheson,et al.  Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. , 1984, Blood.

[154]  P. Volberding,et al.  B-cell immunodeficiency in acquired immune deficiency syndrome. , 1984, JAMA.

[155]  W. Parks,et al.  Acquired immunodeficiency syndrome in infants. , 1984, The New England journal of medicine.

[156]  J. Mestecky,et al.  Distribution of IgA1-, IgA2-, and J chain-containing cells in human tissues. , 1984, Journal of immunology.

[157]  G. Murata,et al.  Community-acquired bacterial pneumonias in homosexual men: presumptive evidence for a defect in host resistance. , 1984, AIDS research.

[158]  J. Winkelstein,et al.  Complement and the host's defense against the pneumococcus. , 1984, Critical reviews in microbiology.

[159]  M. Chou,et al.  Severe pneumococcal infection in patients with neoplastic disease , 1983, Cancer.

[160]  A. Fauci,et al.  Activation of human B lymphocytes after immunization with pneumococcal polysaccharides. , 1983, The Journal of clinical investigation.

[161]  B. J. OʼNeal,et al.  The risk of sepsis in the asplenic adult , 1982 .

[162]  H. Masur,et al.  An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. , 1981, The New England journal of medicine.

[163]  P. Baker,et al.  Regulation of the antibody response to pneumococcal polysaccharide by thymus-derived cells. , 1981, Reviews of infectious diseases.

[164]  S. Weitzman,et al.  Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. , 1980, The New England journal of medicine.

[165]  S. Feig,et al.  Pneumococcal infections after human bone-marrow transplantation. , 1979, Annals of internal medicine.

[166]  R. Johnston,et al.  Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. , 1978, The New England journal of medicine.

[167]  M. Burr,et al.  Letter: Effects of age and intake on plasma-ascorbic-acid levels. , 1974, Lancet.

[168]  J. Twomey Infections complicating multiple myeloma and chronic lymphocytic leukemia. , 1973, Archives of internal medicine.

[169]  J. Hobbs Hypogammaglobulinaemia in the United Kingdom , 1972 .

[170]  R. Austrian,et al.  PNEUMOCOCCAL BACTEREMIA WITH ESPECIAL REFERENCE TO BACTEREMIC PNEUMOCOCCAL PNEUMONIA. , 1964, Annals of internal medicine.

[171]  C. Janeway,et al.  The gamma globulins. , 1966, Advances in pediatrics.